AZD6738 found to slow some types of children's tumor growth in mouse models

November 2, 2017 by Bob Yirka, Medical Xpress report
Credit: CC0 Public Domain

(Medical Xpress)—A team of researchers from the U.S., Germany and Japan has found that the chemical AZD6738 was able to slow some childhood type tumor growths in mouse models. In their paper published in the journal Science Translational Medicine, the group describes why the application of the chemical represents an entirely new way to treat tumor growth in children.

Prior research has shown that cancer in children is very seldom the same as cancer in adults—in many cases, tumors that grow in children differ markedly from tumors that grow in adults which means they require completely different types of treatment. Unfortunately, treatments for childhood tumors has progressed at a much slower pace than for adults. Just four of them, for example, have been approved for use in the U.S. over the last 25 years. One of the main ways to treat adult tumors is to apply chemicals that serve to actively reduce , an approach that has not worked well with children. To get around that problem, the with this new effort have been studying a that has shown an ability to stop tumor growth by preventing tumor cells from repairing their DNA.

The researchers began by noting that prior research had shown that many types of childhood tumors rely on a DNA pathway called nonhomologous end joining (NHEJ) to survive. That led them to search for a chemical that would disrupt the pathway, preventing the cell from repairing its own DNA. Such tumors, the researchers noted, appear to depend on NHEJ to help them overcome problems with handling the excess amounts of an enzyme called PGBD5 they produce.

After finding that applying the chemical AZD6738 to tumor cells directly prevented them from growing, the team then began testing it in mouse models (mice with human implanted in them). They report that doing so caused two types of tumors to stop growing but did not work against two others. While promising, the researchers acknowledge that the chemical is not likely to represent a means for destroying tumors in human patients even if it were to pass clinical trials. It stops growth but does not decrease size. But that would of course still be a far better outcome for treating patients who have no other options.

Explore further: Elucidating the role of circulating nutrients that fuel tumor growth

More information: Anton G. Henssen et al. Therapeutic targeting of PGBD5-induced DNA repair dependency in pediatric solid tumors, Science Translational Medicine (2017). DOI: 10.1126/scitranslmed.aam9078

Abstract
Despite intense efforts, the cure rates of childhood and adult solid tumors are not satisfactory. Resistance to intensive chemotherapy is common, and targets for molecular therapies are largely undefined. We have found that the majority of childhood solid tumors, including rhabdoid tumors, neuroblastoma, medulloblastoma, and Ewing sarcoma, express an active DNA transposase, PGBD5, that can promote site-specific genomic rearrangements in human cells. Using functional genetic approaches, we discovered that mouse and human cells deficient in nonhomologous end joining (NHEJ) DNA repair cannot tolerate the expression of PGBD5. In a chemical screen of DNA damage signaling inhibitors, we identified AZD6738 as a specific sensitizer of PGBD5-dependent DNA damage and apoptosis. We found that expression of PGBD5, but not its nuclease activity–deficient mutant, was sufficient to induce sensitivity to AZD6738. Depletion of endogenous PGBD5 conferred resistance to AZD6738 in human tumor cells. PGBD5-expressing tumor cells accumulated unrepaired DNA damage in response to AZD6738 treatment and underwent apoptosis in both dividing and G1-phase cells in the absence of immediate DNA replication stress. Accordingly, AZD6738 exhibited nanomolar potency against most neuroblastoma, medulloblastoma, Ewing sarcoma, and rhabdoid tumor cells tested while sparing nontransformed human and mouse embryonic fibroblasts in vitro. Finally, treatment with AZD6738 induced apoptosis and regression of human neuroblastoma and medulloblastoma tumors engrafted in immunodeficient mice in vivo. This effect was potentiated by combined treatment with cisplatin, including substantial antitumor activity against patient-derived primary neuroblastoma xenografts. These findings delineate a therapeutically actionable synthetic dependency induced in PGBD5-expressing solid tumors.

Related Stories

Elucidating the role of circulating nutrients that fuel tumor growth

October 19, 2017
Tumors acquire nutrition necessary for generating energy and building blocks for growth and survival from the body of the patient in which they reside.  Although these nutrients are predominantly provided by the circulating ...

A metabolic treatment for pancreatic cancer?

August 15, 2017
Pancreatic cancer is now the third leading cause of cancer mortality. Its incidence is increasing in parallel with the population increase in obesity, and its five-year survival rate still hovers at just 8 to 9 percent. Research ...

Researchers use genetically modified circulating tumor cells to kill other tumors

February 9, 2016
(Medical Xpress)—An international team of medical researchers has found a way to use a kind of cancer cell as a cargo vessel of sorts to kill already existing tumors. In their paper published in Proceedings of the National ...

Study provides insight into link between two rare tumor syndromes

August 22, 2017
UCLA researchers have discovered that timing is everything when it comes to preventing a specific gene mutation in mice from developing rare and fast-growing cancerous tumors, which also affects young children. This mutation ...

Study reaffirms the belief that malignant cell behavior is influenced by the tumor tissue of origin

September 9, 2016
(Medical Xpress)—A team of researchers affiliated with several institutions in the U.S. has conducted a study of cancer in mice and found evidence that reaffirms results from prior research suggesting that malignant cell ...

Scientists stimulate immune system, stop cancer growth

March 1, 2017
A chemical found in tumors may help stop tumor growth, according to a new study.

Recommended for you

DNA vaccine leads to immune responses in HPV-related head and neck cancer

September 21, 2018
A therapeutic vaccine can boost antibodies and T cells, helping them infiltrate tumors and fight off human papillomavirus (HPV)-related head and neck cancer. Researchers from the Abramson Cancer Center of the University of ...

In zebrafish, a way to find new cancer therapies, targeting tumor modulators

September 21, 2018
The lab of Leonard Zon, MD, at Boston Children's Hospital has long been interested in making blood stem cells in quantity for therapeutic purposes. Looking for a way to test for their presence in zebrafish, their go-to research ...

What can salad dressing tell us about cancer? Think oil and vinegar

September 20, 2018
Researchers led by St. Jude Children's Research Hospital scientists have identified another way the process that causes oil to form droplets in water may contribute to solid tumors, such as prostate and breast cancer. The ...

Novel biomarker found in ovarian cancer patients can predict response to therapy

September 20, 2018
Despite months of aggressive treatment involving surgery and chemotherapy, about 85 percent of women with high-grade wide-spread ovarian cancer will have a recurrence of their disease. This leads to further treatment, but ...

Testing fluorescent tracers used to help surgeons determine edges of breast cancer tumors

September 20, 2018
A team of researchers with members from institutions in The Netherlands and China has conducted a test of fluorescent tracers meant to aid surgeons performing tumor removal in breast cancer patients. In their paper published ...

Cancer immunotherapy might benefit from previously overlooked immune players

September 20, 2018
Cancer immunotherapy—efforts to boost a patient's own immune system, allowing it to better fight cancer cells on its own—has shown great promise for some previously intractable cancers. Yet immunotherapy doesn't work ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.